DRKS00024430招募中未知
Stopping contact precautions in patients with 3MRGN on ICU in Germany - SIMo
Institut für Hygiene und Umweltmedizin, Charité Berlin0 个研究点目标入组 70 人开始时间: 2021年4月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Surveillance in KISS-ITS (MRGN), Observation of Handhygienic Compliance
排除标准
- •Interventions are already conducted in this ward, not willing to participate in KISS-ITS Surveillance and handhygienic observations
研究者
相似试验
进行中（未招募）
2 期
Carriage of 3GCREB in patients at risk for relapsing infection: randomizedcontrolled trial of intestinal decolonization with colistin plus rifaximiA04.9Bacterial intestinal infection, unspecifiedDRKS00006330niversitätsklinikum Freiburg3
进行中（未招募）
1 期
randomized controlled trial of intestinal decolonization with colistin plus rifaximin.Intestinal carriage of 3GCREB responsible for relapsing infectionEUCTR2014-000180-41-DEMedical Center - University of Freiburg
进行中（未招募）
1 期
A Phase 3 Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - PRELUDEhigh-risk diffuse large B-cell lymphoma (DLBCL )EUCTR2005-004630-41-BEEli Lilly and Company limited459
已完成
3 期
A Phase 3b Clinical Study To Assess Whether Regular Administration Of Advate In The Absence Of Immunological Danger Signals Reduces The Incidence Rate Of Inhibitors In Previously Untreated Patients With Hemophilia ACoagulation Factor VIII deficiency / Blood disease10018849NL-OMON35535Baxter6
进行中（未招募）
1 期
A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With Nonsegmental VitiligoON SEGMENTAL VITILIGOCTIS2023-505804-42-00Pfizer Inc.490